(Repeats story without changes)
COPENHAGEN, June 26 Novo Nordisk (NOVOb.CO) said
on Saturday a Phase II clinical trial indicated its long-acting
experimental degludec insulin has potential to lower blood sugar
levels effectively, even when used only three times a week.
The world's biggest insulin maker said in a statement the
next-generation insulin showed "potential to help achieve target
glycaemic control when used once daily or three times weekly.
"(Blood sugar) reductions were similar across the once-daily
and three-times-weekly insulin degludec groups ... and
comparable to insulin glargine," the Danish group said.
Degludec is a potential fierce competitor to glargine,
marketed as Lantus by Sanofi-Aventis (SASY.PA), and also to
Novo's own modern insulin Levemir.
"In this study, 77 percent of patients treated with insulin
degludec three times weekly did not experience any confirmed
hypoglycaemia," Novo said. "This result was similar in the study
arm using insulin glargine once daily."
With once-daily injections, 92 percent experienced no
hypoglycaemia, a potentially dangerous over-reduction in blood
The study was presented at the American Diabetes
Association's (ADA) yearly conference in Orlando, Florida.
IDegAsp, also known as degludecplus -- a combination of
degludec and Novo's fast-acting aspart insulin -- taken once
daily brought the majority of patients to ADA-recommended
glycaemic targets without major hypoglycaemia, Novo said.
"In this proof-of-concept trial, there were 60 patients
taking insulin glargine and 59 on IDegAsp with comparable
glycaemic control," it said.
(Reporting by Anna Ringstrom; Editing by David Cowell)